Beam Therapeutics (BEAM) Conference presentation summary
Event summary combining transcript, slides, and related documents.
Conference presentation summary
4 Aug, 2026Disease overview and unmet need
Phenylketonuria (PKU) is a genetic metabolic disorder caused by recessive mutations in the PAH gene, leading to neurotoxicity from elevated phenylalanine (Phe) levels.
Symptoms range from intellectual disability in children to cognitive impairment and psychiatric issues in adults, with risks for newborns of affected mothers.
Management requires strict lifelong dietary restrictions and medical food, with current therapies offering limited efficacy and significant burden.
Many patients struggle to maintain target Phe levels, resulting in suboptimal disease control.
BEAM-304 platform and preclinical development
BEAM-304 is a base editing gene therapy platform targeting PKU, aiming for significant and sustained Phe reduction and potential diet normalization.
BEAM-304A targets the common PAH-p.R408W mutation using an adenine base editor delivered via mRNA-LNPs.
A single dose in mice resulted in potent, precise liver editing and dose-dependent reductions in plasma Phe below clinical targets, with effects seen in both homozygous and compound heterozygous models.
Editing and Phe reduction occurred rapidly and were durable for at least 90 days post-dose.
Platform expansion and clinical development
BEAM-304B is being developed to target a second PKU mutation, using the same delivery platform but different editor and guide RNA, potentially covering nearly half of US PKU patients.
BEAM-304B also demonstrated potent editing and Phe reduction in preclinical models.
Learnings from BEAM-304A are expected to expedite development and regulatory pathways for future variants, leveraging platform synergies and FDA guidance.
A Phase 1/2 open-label, single-ascending dose trial for BEAM-304A in PKU patients with the R408W mutation is planned, focusing on safety, tolerability, and Phe reduction.
Latest events from Beam Therapeutics
- BEAM-302 advances toward pivotal follow-up as risto-cel targets a December 2026 BLA.BEAM
Jefferies Global Healthcare Conference - Positive sickle cell results, advancing AAT enrollment and striking early GSD1a data drive the pipeline.BEAM
UBS Global Biopharma Conference 2026 - Risto-cel nears BLA filing as in vivo editing programs advance.BEAM
3rd Annual Guggenheim Healthcare Innovation Conference - Clinical programs advanced as Q3 losses widened and runway extended into mid-2029, subject to facility conditions.BEAM
Q3 2026 - Two of three patients at 40 mg reached 15-hour fasting and stopped starch supplementation.BEAM
Study result - Gene editing pipeline advances with durable results, strong safety, and first-mover advantage.BEAM
12th Annual Cantor Fitzgerald Global Healthcare Conference - Advancing curative gene therapies with strong financials and pivotal clinical milestones in 2026.BEAM
Corporate presentation - BEAM-302 gene editing achieved sustained, functional AAT restoration and was well tolerated.BEAM
European Respiratory Society Congress presentation - Advancing pivotal gene editing programs with strong data, regulatory momentum, and platform scalability.BEAM
Citigroup’s Biopharma Back to School Summit 2026 - Durable AAT restoration and >80% Z-AAT reduction advance toward pivotal approval.BEAM
Status update